Stock JBCHEPHARM J. B. CHEMICALS & PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials J. B. Chemicals & Pharmaceuticals Limited

Equities

JBCHEPHARM

INE572A01036

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 11:00:56 21/06/2024 BST 		5-day change 1st Jan Change
1,760 INR -2.54% Intraday chart for J. B. Chemicals & Pharmaceuticals Limited -6.88% +8.33%
05-22 Jefferies Adjusts JB Chemicals & Pharmaceuticals' Price Target to INR2,060 From INR2,000, Keeps at Buy MT
05-21 Transcript : J. B. Chemicals & Pharmaceuticals Limited, Q4 2024 Earnings Call, May 21, 2024

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 28,853 39,286 96,881 121,735 152,503 273,136 - -
Enterprise Value (EV) 1 28,853 39,286 96,881 121,735 155,518 255,986 267,927 262,874
P/E ratio 15.3 x 14.9 x 21.6 x 31.6 x 37.7 x 47.3 x 39.1 x 32 x
Yield 1.39% 2.16% 1.32% 1.05% 0.9% 0.63% 0.8% 0.91%
Capitalization / Revenue 1.76 x 2.21 x 4.74 x 5.02 x 4.84 x 7.35 x 6.73 x 5.95 x
EV / Revenue 1.76 x 2.21 x 4.74 x 5.02 x 4.94 x 7.35 x 6.6 x 5.73 x
EV / EBITDA 9.45 x 10.4 x 17.3 x 22.4 x 22.4 x 28.5 x 24.7 x 20.8 x
EV / FCF 19.9 x 19.4 x 36.3 x 113 x 28.1 x 61.5 x 41.3 x 33 x
FCF Yield 5.02% 5.15% 2.76% 0.88% 3.56% 1.62% 2.42% 3.03%
Price to Book 2 x 2.82 x 5.35 x 5.7 x 6.15 x 8.36 x 7.23 x 6.04 x
Nbr of stocks (in thousands) 160,473 154,564 154,564 154,564 154,755 155,213 - -
Reference price 2 179.8 254.2 626.8 787.6 985.4 1,760 1,760 1,760
Announcement Date 21/05/19 25/06/20 14/06/21 26/05/22 24/05/23 17/05/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 16,432 17,747 20,425 24,242 31,493 34,842 40,581 45,883
EBITDA 1 3,054 3,776 5,604 5,435 6,958 8,969 10,832 12,655
EBIT 1 2,912 3,113 4,917 4,708 5,813 7,586 9,294 11,208
Operating Margin 17.72% 17.54% 24.08% 19.42% 18.46% 21.77% 22.9% 24.43%
Earnings before Tax (EBT) 1 2,870 3,489 5,969 5,049 5,552 7,515 9,434 11,586
Net income 1 1,940 2,720 4,480 3,854 4,098 5,526 7,009 8,615
Net margin 11.8% 15.33% 21.93% 15.9% 13.01% 15.86% 17.27% 18.78%
EPS 2 11.77 17.10 28.98 24.91 26.17 34.85 45.04 55.02
Free Cash Flow 1 1,447 2,024 2,670 1,073 5,530 4,460 6,484 7,974
FCF margin 8.81% 11.4% 13.07% 4.42% 17.56% 12.74% 15.98% 17.38%
FCF Conversion (EBITDA) 47.39% 53.61% 47.65% 19.74% 79.49% 48.75% 59.86% 63.01%
FCF Conversion (Net income) 74.62% 74.4% 59.61% 27.84% 134.94% 79.06% 92.51% 92.56%
Dividend per Share 2 2.500 5.500 8.250 8.250 8.875 11.10 14.14 15.93
Announcement Date 21/05/19 25/06/20 14/06/21 26/05/22 24/05/23 17/05/24 - -
1INR in Million2INR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 5,482 5,285 6,060 5,930 6,007 6,246 7,848 8,094 7,927 7,623 8,962 8,986 8,629 8,603
EBITDA 1 1,710 1,239 1,637 1,267 1,117 1,249 1,728 1,846 1,748 1,636 2,321 2,307 2,289 1,990
EBIT - - - - - - - - - - - - - -
Operating Margin - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 - - - - - - - 1,489 1,412 1,225 1,943 1,949 1,919 1,584
Net income 1 1,541 1,006 1,189 977.5 838.9 848.4 1,050 1,111 1,061 876.3 1,423 1,409 1,413 1,201
Net margin 28.11% 19.04% 19.62% 16.48% 13.97% 13.58% 13.38% 13.72% 13.38% 11.5% 15.88% 15.68% 16.37% 13.96%
EPS 2 - - 7.690 6.315 5.410 5.480 - - 6.785 - 9.070 9.405 9.390 7.567
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 10/02/21 14/06/21 12/08/21 11/11/21 14/02/22 26/05/22 04/08/22 11/11/22 08/02/23 24/05/23 09/08/23 - - -
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - 3,015 1,319 - -
Net Cash position 1 - - - - - - 5,209 10,262
Leverage (Debt/EBITDA) - - - - 0.4333 x 0.1441 x - -
Free Cash Flow 1 1,447 2,024 2,670 1,073 5,530 4,460 6,484 7,974
ROE (net income / shareholders' equity) 13.3% 18.7% 27.6% 19.5% 17.8% 20.7% 21.8% 22.4%
ROA (Net income/ Total Assets) - - - - 13.3% 14% 16% 17%
Assets 1 - - - - 30,806 40,289 43,805 50,675
Book Value Per Share 2 89.80 90.20 117.0 138.0 160.0 210.0 243.0 291.0
Cash Flow per Share 2 - - - 11.00 40.40 47.70 53.30 62.30
Capex 1 483 730 478 629 726 2,046 842 857
Capex / Sales 2.94% 4.11% 2.34% 2.59% 2.3% 5.84% 2.07% 1.87%
Announcement Date 21/05/19 25/06/20 14/06/21 26/05/22 24/05/23 17/05/24 - -
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for J. B. Chemicals & Pharmaceuticals Limited

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
1,760 INR
Average target price
1,971 INR
Spread / Average Target
+12.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
J. B. CHEMICALS & PHARMACEUTICALS LIMITED Stock J. B. Chemicals & Pharmaceuticals Limited
+8.33% 3.35B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.63% 798B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.51% 633B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.10% 356B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.90% 328B
ABBVIE INC. Stock AbbVie Inc.
+9.95% 304B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.66% 244B
ROCHE HOLDING AG Stock Roche Holding AG
+3.39% 227B
NOVARTIS AG Stock Novartis AG
+10.75% 216B
AMGEN INC. Stock Amgen Inc.
+6.99% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. JBCHEPHARM Stock
  4. Financials J. B. Chemicals & Pharmaceuticals Limited